Attorney Advertising-- NEW YORK, Jan. 08, 2018 -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Philip Morris International Inc. ("Philip Morris" or the "Company") (NYSE:PM) and certain of its officers, on behalf of shareholders who purchased Philip Morris securities between July 26, 2016 and December 20, 2017, both dates inclusive (“Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/pm.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The complaint alleges that Defendants made false and/or misleading statements and failed to disclose that: (1) there were irregularities in the clinical experiments that underpin Philip Morris’ application to the FDA for approval of its iQOS smoking device; and (2) consequently, defendants’ statements about Philip Morris’ business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/pm or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Philip Morris you have until February 20, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Samsung Electronics Shares Jump on HBM4 Mass Production Report
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Anta Sports Expands Global Footprint With Strategic Puma Stake
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 



